Sponsor or institution
Clinical trials and research at PersonGen BioTherapeutics (Suzhou) Co., Ltd.
As of November 12, 2026, Find a Trial lists 7 clinical trials run by PersonGen BioTherapeutics (Suzhou) Co., Ltd. that are recruiting, in China. By phase: Early Phase 1 (3), Phase 1 (2), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 7Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| UTAA07 CAR-γδT cell infusion for relapsed or refractory CD7-positive blood and lymphoid cancers | Early Phase 1 | Suzhou, Jiangsu | Recruiting | Jan 14, 2026 |
| LV009 infusion for relapsed/refractory CD19-positive blood cancers | Early Phase 1 | Hefei, Anhui | Recruiting | Dec 31, 2025 |
| LV009 injection for relapsed or refractory CD19-positive blood and lymph cancers | Phase 1 | Suzhou, Jiangsu | Recruiting | Dec 16, 2025 |
| PA3-17 (CD7-targeted CAR-T) injection for adults with CD7-positive relapsed/refractory T-lymphoblastic leukemia/lymphoma | Phase 2 | Hefei, Anhui and 15 other locations | Recruiting | Sep 23, 2025 |
| UTAA17 injection for treating relapsed or refractory multiple myeloma | — | Suzhou, Jiangsu | Recruiting | Feb 26, 2024 |
| UTAA09 injection for treating relapsed or refractory B-cell cancers | Early Phase 1 | Hefei, Anhui | Recruiting | Oct 23, 2023 |
| TAA06 injection for treating B7-H3-positive neuroblastoma | Phase 1 | Jinan, Shandong and 1 other locations | Recruiting | Sep 30, 2022 |
All recruiting trials (7)
-
UTAA07 CAR-γδT cell infusion for relapsed or refractory CD7-positive blood and lymphoid cancers
This study will try UTAA07 CAR-γδT cell infusions in adults with relapsed or refractory CD7-positive hematologic and lymphoid cancers to see if they are safe and help control the disease.
-
LV009 infusion for relapsed/refractory CD19-positive blood cancers
This early-phase study will test whether LV009 infusion is safe and how it behaves in adults with relapsed or refractory CD19-positive blood cancers such as NHL or ALL.
-
LV009 injection for relapsed or refractory CD19-positive blood and lymph cancers
This will test whether LV009 injections are safe for adults with relapsed or refractory CD19-positive non-Hodgkin lymphoma or acute lymphoblastic leukemia.
-
PA3-17 (CD7-targeted CAR-T) injection for adults with CD7-positive relapsed/refractory T-lymphoblastic leukemia/lymphoma
This will test a single infusion of PA3-17, a CD7-targeted CAR-T, in adults with CD7-positive relapsed or refractory T-lymphoblastic leukemia/lymphoma.
-
UTAA17 injection for treating relapsed or refractory multiple myeloma
This study is testing a new injection called UTAA17 to see if it can safely help people with relapsed or refractory multiple myeloma.
-
UTAA09 injection for treating relapsed or refractory B-cell cancers
This study is testing a new cell treatment called UTAA09 to see if it can help people with certain types of B-cell cancers that have come back or didn't respond to other treatments.
-
TAA06 injection for treating B7-H3-positive neuroblastoma
This study is testing a new T cell injection called TAA06 to see if it can safely help patients with hard-to-treat neuroblastoma that has come back.
Quick answers
How many clinical trials run by PersonGen BioTherapeutics (Suzhou) Co., Ltd. are recruiting right now?
7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Early Phase 1: 3, Phase 1: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.